| Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis Lancet 352 (9139), 1491-1497, 1998 | 749 | 1998 |
| Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS C Munch, R Sedlmeier, T Meyer, V Homberg, AD Sperfeld, A Kurt, ... Neurology 63 (4), 724-726, 2004 | 530 | 2004 |
| Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study E Nelis, C Van Broeckhoven, P De Jonghe, A Löfgren, A Vandenberghe, ... European Journal of Human Genetics 4 (1), 25-33, 1996 | 517 | 1996 |
| The peripheral myelin protein gene PMP–22 is contained within the Charcot–Marie–Tooth disease type 1A duplication V Timmerman, E Nelis, W Van Hul, BW Nieuwenhuijsen, KL Chen, ... Nature genetics 1 (3), 171-175, 1992 | 450 | 1992 |
| Peripheral myelin protein–22 gene maps in the duplication in chromosome 17p11. 2 associated with Charcot–Marie–Tooth 1A N Matsunami, B Smith, L Ballard, M William Lensch, M Robertson, ... Nature genetics 1 (3), 176-179, 1992 | 372 | 1992 |
| Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4DCAF1 in the nucleus W Li, L You, J Cooper, G Schiavon, A Pepe-Caprio, L Zhou, R Ishii, ... Cell 140 (4), 477-490, 2010 | 369 | 2010 |
| Merlin/NF2 loss-driven tumorigenesis linked to CRL4DCAF1-mediated inhibition of the Hippo pathway kinases Lats1 and 2 in the nucleus W Li, J Cooper, L Zhou, C Yang, H Erdjument-Bromage, D Zagzag, ... Cancer cell 26 (1), 48-60, 2014 | 247 | 2014 |
| Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD C Münch, A Rosenbohm, AD Sperfeld, I Uttner, S Reske, BJ Krause, ... Annals of Neurology: Official Journal of the American Neurological …, 2005 | 237 | 2005 |
| Schwannomas and their pathogenesis DA Hilton, CO Hanemann Brain pathology 24 (3), 205-220, 2014 | 217 | 2014 |
| Axon‐regulated expression of a Schwann cell transcript that is homologous to a ‘growth arrest‐specific’gene. P Spreyer, G Kuhn, CO Hanemann, C Gillen, H Schaal, R Kuhn, G Lemke, ... The EMBO journal 10 (12), 3661-3668, 1991 | 212 | 1991 |
| X-linked bulbospinal neuronopathy: Kennedy disease AD Sperfeld, J Karitzky, D Brummer, H Schreiber, J Häussler, AC Ludolph, ... Archives of Neurology 59 (12), 1921-1926, 2002 | 199 | 2002 |
| DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management F Nassiri, Y Mamatjan, S Suppiah, JH Badhiwala, S Mansouri, S Karimi, ... Neuro-oncology 21 (7), 901-910, 2019 | 196 | 2019 |
| Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria SR Plotkin, JO Blakeley, DG Evans, CO Hanemann, TJM Hulsebos, ... American journal of medical genetics Part A 161 (3), 405-416, 2013 | 193 | 2013 |
| Dissecting and targeting the growth factor–dependent and growth factor–independent extracellular signal-regulated kinase pathway in human schwannoma S Ammoun, C Flaiz, N Ristic, J Schuldt, CO Hanemann Cancer research 68 (13), 5236-5245, 2008 | 157 | 2008 |
| Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2 AD Sperfeld, C Hein, JM Schröder, AC Ludolph, CO Hanemann Brain 125 (5), 996-1004, 2002 | 155 | 2002 |
| Accumulation of autophagosomes confers cytotoxicity RW Button, SL Roberts, TL Willis, CO Hanemann, S Luo Journal of Biological Chemistry 292 (33), 13599-13614, 2017 | 152 | 2017 |
| Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial A Al-Chalabi, C Allen, C Counsell, A Farrin, B Dickie, J Kelly Lancet Neurol 12 (4), 339-45, 2013 | 143 | 2013 |
| Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells K Kaempchen, K Mielke, T Utermark, S Langmesser, CO Hanemann Human molecular genetics 12 (11), 1211-1221, 2003 | 142 | 2003 |
| Transient, recurrent, white matter lesions in X-linked Charcot-Marie-Tooth disease with novel connexin 32 mutation CO Hanemann, C Bergmann, J Senderek, K Zerres, AD Sperfeld Archives of neurology 60 (4), 605-609, 2003 | 142 | 2003 |
| Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2 JO Blakeley, DG Evans, J Adler, D Brackmann, R Chen, RE Ferner, ... American journal of medical genetics Part A 158 (1), 24-41, 2012 | 134 | 2012 |
